Scientists race to develop Ebola drugs as outbreak surges

"Scientists are racing to trial experimental treatments and potentially vaccines against a rare Ebola species that is spreading in the Democratic Republic of the Congo (DRC) and Uganda. There are no approved treatments or vaccines against Ebola Bundibugyo virus, which has been linked to 336 suspected cases and 88 deaths, according to data from the US Centers for Disease Control and Prevention as of on 17 May."

"Nature has learnt that a World Health Organization (WHO)-sponsored clinical trial of two experimental treatments for Ebola Bundibugyo virus disease is in the works, pending approval by the governments of DRC and Uganda. Health officials are also considering whether an approved vaccine for another species of Ebola virus could be trialled in the current outbreak."

"“I think we're in a really strong position to quickly launch trials,” says Amanda Rojek, a clinical researcher at the University of Oxford, UK, who is part of the treatments trial. “We're working day and night at the moment.”"

"Rojek, who is part of a WHO effort to rapidly trial treatments against filoviruses, which includes Ebola and Marburg viruses, during outbreaks, says the trial will focus on two therapies. One is the broad-acting antiviral called remdesivir, which is manufactured by Gilead Sciences in Foster City, California. The other is a treatment called MBP134, which is a mixture of two antibodies that recognize diverse Ebola viruses and was developed by Mapp Biopharmaceuticals in San Diego, California."

A rare Ebola species, Ebola Bundibugyo virus, is spreading in the Democratic Republic of the Congo and Uganda. No approved treatments or vaccines exist for this virus. Reported figures include 336 suspected cases and 88 deaths as of 17 May, based on US Centers for Disease Control and Prevention data. A WHO-sponsored clinical trial is planned to test two experimental therapies, pending approval from the governments of DRC and Uganda. The therapies are remdesivir, a broad-acting antiviral, and MBP134, a mixture of two antibodies designed to recognize diverse Ebola viruses. Health officials are also considering whether an approved vaccine for another Ebola species could be tested in the outbreak.

Read at www.nature.com